Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Diagnostics » Burrill CEO Discusses Pharma’s Evolving Role, Projects Generic Saturation in Dx Market

Burrill CEO Discusses Pharma’s Evolving Role, Projects Generic Saturation in Dx Market

Nov 21, 2007
Premium
SAN FRANCISCO – As the healthcare infrastructure moves away from a one-size-fits-all model to a more personalized paradigm, and pharmacogenomic technologies shift the economic focus from the development of blockbusters to niche-busters, large drug companies’ sales prowess will be what saves them, according to Burrill & Company CEO Steven Burrill.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Breathe It Out

Researchers are developing a breath test to determine how severe patients' methylmalonic acidemia disease is, FierceBiotech reports.

The Next Batch

NPR reports that vaccine developers are working on SARS-CoV-2 vaccines that are easier to store or administer than the current crop.

Switch for the Second

Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.

Science Reviews How Non-Genetic DNA Features Expand Utility of Liquid Biopsies, Presents Study of Enzymes in DNA Methylation

In Science this week: review discusses advances in liquid biopsies, and more.

Apr
13
Featured Webinar

An Opportunity Arises from the Pandemic: The Promise of Targeted NGS for SARS-CoV-2 Detection

Sponsored by
Beckman Coulter Life Sciences

Mitigation of the SARS-CoV-2 pandemic will continue to require innovative solutions. This webinar will outline how Fry Laboratories rapidly redeployed a next-generation sequencing (NGS) pipeline originally created for the detection and identification of bacterial, eukaryotic, and fungal infections in response to SARS-CoV-2.

Apr
16
Featured Webinar

The Post-Vaccine COVID Testing Landscape: A Virtual Roundtable Discussion

Sponsored by
Thermo Fisher Scientific

With COVID-19 vaccines rolling out, clinical labs and test developers are preparing for changes in both demand for testing and types of testing for SARS-CoV-2.

Apr
21
Featured Webinar

Single-cell Multiomics Analysis of Clonal Evolution in Myeloid Malignancies

Sponsored by
Mission Bio

This webinar, the first in a “Meet the Authors” series sponsored by Mission Bio, will discuss the application of single-cell analysis to decipher clonal evolution across several stages of disease development in myeloid malignancies. 

Apr
27
Featured Webinar

Oncology in the Time of COVID-19: Quantitative Proteomic Analysis of Anti-IL6 Treated Patients

Sponsored by
Biognosys

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.